Skip to main content

Advertisement

SpringerLink
Log in

Travoprost

  • Adis New Drug Profile
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

  • ▲ Travoprost is a synthetic ester prodrug of a prostaglandin F2α analogue used in the treatment of open-angle glaucoma and ocular hypertension.

  • ▲ Intraocular travoprost 0.004% once daily was significantly more effective at reducing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension than placebo or timolol 0.5% twice daily and was at least as effective as latanoprost 0.005% once daily in randomised, double-blind studies.

  • ▲ When used as adjunctive therapy with timolol 0.5% twice daily in patients with elevated IOP not adequately controlled by timolol alone, travoprost 0.004% showed significant additional IOP reduction in a randomised double-blind trial.

  • ▲ Travoprost 0.004% was well tolerated in clinical trials. The majority of adverse events such as ocular hyperaemia and eyelash changes were mild and resolved without treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Orengo-Nania S, Landry T, Von Tress M, et al. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001 Dec; 132(6): 860–8

    Article  PubMed  CAS  Google Scholar 

  2. Netland PA, Landry T, Sullivan EK, et al., on behalf of the Travaprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001 Oct; 132(4): 472–84

    Article  PubMed  CAS  Google Scholar 

  3. Periodic health examination, 1995 update: 3. Screening for visual problems among elderly patients. Canadian Task Force on the Periodic Health Examination. CMAJ 1995 Apr 15; 152(8): 1211–22

    Google Scholar 

  4. Alward WLM. Medical management of glaucoma. N Engl J Med 1998 Oct 29; 339(18): 1298–307

    Article  PubMed  CAS  Google Scholar 

  5. Diggory P, Franks WA. Glaucoma therapy may take your breath away. Age Ageing 1997 Mar; 26: 63–7

    Article  PubMed  CAS  Google Scholar 

  6. Diamond JP. Systemic adverse effects of topical ophthalmic agents: implications for older patients. Drugs Aging 1997 Nov; 11(5): 352–60

    Article  PubMed  CAS  Google Scholar 

  7. Linden C, Alm A. Prostaglandin analogues in the treatment of glaucoma. Drugs Aging 1999 May; 14(5): 387–98

    Article  PubMed  CAS  Google Scholar 

  8. Baker DE. Current FDA-related drug information: new drugs approved by the FDA. New dosage forms and indications. Agents pending FDA approval. Hosp Pharm 2001; 36(7): 773–85

    Google Scholar 

  9. Alcon’s Travatan OKd by CPMP. Scrip 2001 Aug 1; (No. 2665): 22

  10. Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther 2001 Oct; 17(5): 421–32

    Article  PubMed  CAS  Google Scholar 

  11. Davis TL, Sharif NA. Pharmacological characterization of [3H]-prostaglandin E2 binding to the cloned human EP4 prostanoid receptor. Br J Pharmacol 2000; 130(8): 1919–26

    Article  PubMed  CAS  Google Scholar 

  12. Sharif NA, Davis TL, Williams GW. [3H]AL-5848 ([3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol 1999 Jun; 51(6): 685–94

    Article  PubMed  CAS  Google Scholar 

  13. Schachtschabel U, Lindsey JD, Weinreb RN. Mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol 2000; 11: 112–5

    Article  PubMed  CAS  Google Scholar 

  14. Camras CB. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. Adv Prostaglandin Thromboxane Leukot Res 1995; 23: 519–25

    PubMed  CAS  Google Scholar 

  15. Goldberg I, Cunha-Vaz J, Jakobsen J., on behalf of the International Travoprost Study Group. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001 Oct; 10(5): 414–22

    Article  PubMed  CAS  Google Scholar 

  16. European Agency for the Evaluation of Medicinal Products. Travoprost: summary of product characteristics [online]. Available from URL: www.eudra.org/humandocs/humans/epar/travatan.travatan.htm [Accessed 2002 Feb 28]

  17. Garadi R, Silver L, Landry T, et al. Travoprost: a new once-daily dosed prostaglandin for the reduction of elevated intraouclar pressure [abstract]. Invest Ophthalmol Vis Sci Mar 1999; 40(4): 4378

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    John Waugh & Blair Jarvis

Authors
  1. John Waugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Blair Jarvis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Waugh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Waugh, J., Jarvis, B. Travoprost. Drugs Aging 19, 465–471 (2002). https://doi.org/10.2165/00002512-200219060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200219060-00005

Keywords

Search

Navigation